Synthesis of (\pm) -Ambrox from (*E*)-Nerolidol and β -Ionone *via* Allylic Alcohol [2,3] **Sigmatropic Rearrangement**

Alejandro F. Barrero, *,[†] Joaquín Altarejos,[‡] Enrique J. Alvarez-Manzaneda,[†] José M. Ramos,[†] and Sofía Salido[†]

Departamento de Química Orgánica, Facultad de Ciencias, Universidad de Granada, 18071 Granada, Spain, and Departamento de Química Inorgánica y Orgánica, Facultad de Ciencias Experimentales, Universidad de Jaén, 23071 Jaén, Spain

Received October 26, 1995

Ambergris is a metabolite of sperm whales (Physeter macrocephalus L.) which accumulates as concretions in the gut of the animal.¹ After several years of aging, as a result of the action of sunlight, air, and water, the final ambergris combines a unique odor with fixative properties particularly prized by perfumers. Release of the ambergris fragrance is related principally to the presence of the (-)-norlabdane oxide **1**, registered by Firmenich S. A. under the trademark Ambrox, which has inherited the best attributes of the increasingly more scarce natural material, and today constitutes its most important commercial substitute. This fact has prompted chemists to develop synthetic routes for the production of (–)-ambrox as well as for the racemic compound (\pm)ambrox whose odor is somewhat different² from that of the natural product. Since its initial preparation in 1950,³ several syntheses of (-)-ambrox have been developed from naturally-occurring sesquiterpenes or diterpenes such as (-)-drimenol,⁴ (-)-sclareol,^{3,5} (-)-manoyl oxide,⁶ (-)-abietic acid,⁷ (-)-levopimaric acid⁸ and (-)labdanolic acid,⁹ and recently, from the monoterpenes (+)-carvone¹⁰ and thujone.¹¹ With respect to the race-

[†] Universidad de Granada.

(1) Ohloff, G. The Fragrance of Ambergris. In Fragrance Chemistry; Theimer, E. T., Ed.; Academic Press: New York, 1982; pp 535-573. (2) (+)-Ambrox has an accentuated woody odor but does not possess

the strong, warm animal note of its enantiomer (–)-1: Ohloff, G.; Giersch, W.; Pickenhagen, W.; Furrer, A. y Frei, B., *Helv. Chim. Acta* 1985, 68, 2022-2029.

(3) (a) Stoll, M.; Hinder, M. *Helv. Chim. Acta* 1950, *33*, 1251–1261.
(b) Hinder, M; Stoll, M. *Ibid.* 1308–1312.

(4) González-Sierra, M.; Rúveda, E. A.; López, J. T.; Cortés, M. J. *Heterocycles* **1987**, *26*, 2801–2804.

 (5) For some references see: (a) Ogura, T.; Matsuoka, H.; Yamanaka, T. Jpn. Kokai Tokkyo Koho JP 6,133,184 [*Chem. Abstr.* 1986, 105, 134193k].
 (b) Decorzant, R.; Vial, C.; Näf, F.; Whitesides, G. M. Tetrahedron 1987, 43, 1871–1879.
 (c) Christenson, P. A. *Ibid.* 1988, 44, 1925–1932. 44. 1925–1932. (d) Coste-Manière, I. C.; Zahra, J. P.; Waegell, B. *Tetrahedron Lett.* 1988, 29, 1017–1020, and references cited therein.
 (e) Farbood, M. I.; Willis, B. J. U. S. US 4,798,799 [*Chem. Abstr.* 1989, 110, 171811j]. (f) Martres, P.; Perfetti, P.; Zahra, J.-P.; Waegell, B.; Giraudi, E.; Petrzilka, M. Tetrahedron Lett. 1993, 34, 629-632. (g) Barton, H. R.; Parekh, S. I.; Taylor, D. K.; Tse, C. Tetrahedron Lett. 1994, 35, 5801-5804. (h) Barton, H. R.; Taylor, D. K.; Tse, C. Ibid. 9505-9508

(6) Cambie, R. C.; Joblin, K. N.; Preston, A. F. Aust. J. Chem. 1971, 24, 583-591.

(7) (a) Koyama, H.; Kaku, Y.; Ohno, M. Tetrahedron Lett. 1987, 28, 2863-2866. (b) Ono, M.; Kine, M. Jpn. Kokai Tokkyo Koho JP 63,162,683 [Chem. Abstr. 1989, 110, 38875s].

(8) Nishi, Y.; Ishihara, H. J. Jpn. Oil Chem. Soc. 1989, 38, 276-279

(9) Urones, J. G.; Basabe, P.; Marcos, I. S.; González, J. L.; Jiménez, V.; Sexmero, M. J.; Lithgow, A. M. Tetrahedron 1992, 48, 9991-9998, and references cited therein.

(10) Verstegen-Haaksma, A. A; Swarts, H. J.; Jansen, B. J. M.;
 Groot, A. *Tetrahedron* 1994, *50*, 10095–10106.
 (11) Kutney, J. P.; Chen, Y.-H. *Can. J. Chem.* 1994, *72*, 1570–1581.

mate (\pm) -ambrox, diverse total syntheses have been performed based on biogenetic-type cyclizations from farnesic acid, monocyclofarnesic acid, or derivatives of these.¹² Among the cyclization agents employed in these processes are SnCl₄,¹³ Sn(OTf)₂,¹⁴ BF₃·Et₂O,¹⁵ CF₃-COOH,¹⁶ HCOOH-H₂SO₄,¹⁷ and more recently the "superacids" FSO₃H^{12c,18} and ClSO₃H.¹⁹

The present authors have recently described the synthesis of levo (-)-ambrox from the labdane-type diterpenes (-)-sclareol,²⁰ (+)-*cis*-abienol,^{20,21} and (+)-communic acids.²² In this context, the authors are now pleased to report new syntheses of racemic (\pm) -ambrox from (+)-(*E*)-nerolidol (3) and β -ionone (11), in which the stereospecific formation of the diastereomer (\pm) -9-epiambrox (2) was also carried out. Compound (-)- $2^{2,23}$ was prepared from (+)-sclareolide² and also through a stereocontrolled enantioselective process based on the anionic oxy-Cope rearrangement.²⁴ The racemate (\pm) -**2** was obtained in superacid cyclizations of hydroxypolyenes.^{12c}



In our approach to (\pm) -ambrox (1) from (+)-(*E*)-nerolidol (3) and β -ionone (11) the key step is the [2,3] sigmatropic rearrangement of an allylic alcohol to the homologous amide²⁵ promoted by heating the corresponding alcohol with N,N-dimethylformamide dimethyl acetal

4053 - 4056

(15) Cassel, J. M.; Hoagland, S. M.; Renga, J. M. PCT Int. Appl. WO 9,206,063 [*Chem. Abstr.* **1992**, *117*, 26848s].

(16) Kawanobe, T.; Kogami, K.; Matsui, M. Agric. Biol. Chem. 1986, 50, 1475-1480.

 (17) Lucius, G. Angew. Chem. 1956, 68, 247.
 (18) For a review see: Vlad, P. F. Pure Appl. Chem. 1993, 65, 1329-1336

(19) (a) Oritani, T.; Yamashita, K. Jpn. Kokai Tokkyo Koho JP 02,258,773 [*Chem. Abstr.* **1991**, *114*, 143747g]. (b) Asanuma, G.; Tamai, H. Jpn. Kokai Tokkyo Koho JP 05,186,453 [Chem. Abstr. 1994, 120, 8779c]

(20) (a) Barrero, A. F.; Alvarez-Manzaneda, E. J.; Ramos, J. M.; Altarejos, J. Span. ES 2,044,780 [Chem. Abstr. 1994, 120, 299025e]. (b) Barrero, A. F.; Alvarez-Manzaneda, E. J.; Altarejos, J.; Salido, S.; Ramos, J. M. Tetrahedron 1993, 49, 10405-10412.

(21) Barrero, A. F.; Sánchez, J. F.; Alvarez-Manzaneda, E. J.; Altarejos, J.; Muñoz, M.; Haïdour, A. Tetrahedron 1994, 50, 6653-6662

(22) (a) Barrero, A. F.; Altarejos, J.; Salido, S. Span. ES 2,069,469 (*chem. Abstr.* **1995**, *123*, 846593c]. (b) Barrero, A. F.; Altarejos, J.; Alvarez-Manzaneda, E. J.; Ramos, J. M.; Salido, S. *Tetrahedron* **1993**, *49*, 6251–6262. (c) Barrero, A. F.; Altarejos, J.; Alvarez-Manzaneda, E. J.; Ramos, J. M.; Salido, S. *Tetrahedron* **1993**, *49*, 9525–9534.

(23) The odor of 2 is of similar strength to that of 1 (0.15 ppb versus 0.30 pb) and differs only slightly from the rich and complex bouquet of 1: Escher, S.; Giersch, W.; Niclass, Y.; Bernardinelli, G.; Ohloff, G. Helv. Chim. Acta 1990, 73, 1935-1947.

(24) (a) Paquette, L. A.; Maleczka, R. E. J. Org. Chem. 1991, 56, 912-913. (b) Maleczka, R. E.; Paquette, L. A. Ibid. 6538-6546.

© 1996 American Chemical Society

[‡] Universidad de Jaén.

^{(12) (}a) For a review see: Sell, C. Chem. Ind. 1990, 516-520, and references cited therein. (b) Snowden, R. L.; Linder, S. Tetrahedron Lett. 1991, 32, 4119-4120. (c) Snowden, R. L.; Eichenberger, J.-C.; Linder, S. M.; Sonnay, P.; Vial, C.; Schulte-Elte, K. H. J. Org. Chem. **1992**, *57*, 955–960. (d) For a recent synthesis see: Barco, A.; Benetti, S.; Bianchi, A.; Casolari, A.; Guarneri, M.; Pollini, G. P. Tetrahedron 1995, 51, 8333-8338.

^{(13) (}a) Saito, A.; Matsushita, H.; Tsujino, Y.; Kisaki, T.; Kato, K.; Noguchi, M. *Chem. Lett.* **1978**, 1065–1068. (b) Saito, A.; Matsushita, H.; Tsujino, Y.; Kaneko, H. *Ibid.* **1981**, 757–760. (c) Saito, A.; Matsushita, H.; Kaneko, H. *Ibid.* **1983**, 729–732. (d) Staiger, G.; Macri, A. Ger. Offen. DE 3,240,054 [Chem. Abstr. 1984, 101, 130928y].
 (14) Gnonlonfoun, N.; Zamarlik, H. Tetrahedron Lett. 1987, 28,

Scheme 1 [2,3] Sigmatropic Rearrangement of (*E*)-Nerolidol (3). Superacid-Mediated Cyclization of 5 into (±)-Ambrox (1) and (±)-9-*epi*-Ambrox (2)



Reaction conditions:

(i) DMFDMA, xylene, reflux, 13h. (ii) LiBEt₃H, THF, -78°C, 7h. (iii) CISO₃H, PrNO₂, -78°C, 6 min.





			product distribution (%) ^a						
entry	starting material	cyclization agent	1	2	6	7	8	9	10
1	5	ClSO ₃ H	45.1	36.5	1.0	0.6	2.9	-	-
2	15a	ClSO ₃ H	47.8	37.7	2.6	0.8	7.0	_	_
3	15b	ClSO ₃ H	0.8	82.9	_	13.2	1.7	2.2	_
4	15a	p-TsOH	0.9	<0.2	_	_	_	_	81.2
5	15a	SnCl ₄	12.3	11.6	_	4.7	4.5	1.7	17.3
6	15a	H_2SO_4	42.3	26.5	—	2.7	5.0	2.4	13.0

^a GC analysis of crude reaction.

(DMFDMA). With this reaction the carbon required to complete the C₁₆-skeleton of ambrox is directly incorporated into either the nerolidol molecule (3) or into the monocyclic alcohol analog 15a, the latter having been prepared from β -ionone in adequate yield. Thus, the refluxing of a mixture of (+)-(E)-nerolidol (3) and DM-FDMA in xylene for 13 h yielded an E/Z mixture of the β , γ -unsaturated amides **4a** and **4b** (2.2:1) in 79% yield (Scheme 1). The easy separation of both amides by column chromatography allowed us to record their spectroscopic data separately and to perform the reduction of 4a with LiBEt₃H in THF at -78 °C to give the alcohol 5 (75% yield). The cyclization of 5 was carried out with the superacid ClSO₃H in 1-nitropropane at -78 °C, giving a diastereomeric mixture formed mainly of (\pm) -1 (41%) yield) and (\pm) -9-epi-ambrox (2) (34% yield).²⁶ Besides these, other minor compounds with a *cis* A/B ring

junction (**6**–**10**) were also analyzed by GC-MS and identified by comparison with authentic samples (Table 1; entry 1).²⁷

In the synthesis from β -ionone (11) the precursor of (\pm) -1 is (*E*)-monocyclohomofarnesol (15a), prepared by reducing the (*E*)-amide 14a, which is obtained through the same [2,3] sigmatropic rearrangement developed in the nerolidol approach, now produced from monocyclonerolidol (13) (Scheme 2). The preliminary preparation of allylic alcohol 13 was accomplished in two steps: (a) the selective Δ^3 hydrogenation of β -ionone (11) using tri*n*-butyltin hydride together with azoisobutyronitrile as a source of free radicals²⁸ to give 12 in 91% yield, and (b) the reaction of 12 with vinylmagnesium bromide in THF at 10 °C to give 13 in 96% yield. The treatment of 15a with ClSO₃H under the same conditions as before led to a mixture of (\pm)-1 (43%) and (\pm)-2 (34%), similar in composition to that obtained from the acyclic analog 5

⁽²⁵⁾ Büchi, G.; Cushman, M.; Wüest, H. J. Am. Chem. Soc. 1974, 96, 5563–5565.

⁽²⁶⁾ These yields were calculated taking into account the percentages recorded by the GC analysis of the crude reaction (Table 1; entry 1) and the loss of weight of cyclized crude material with respect to the starting material **5**.

⁽²⁷⁾ A copy of the original mass spectral charts of compounds **2**, **6-10** were kindly provided by Roger L. Snowden (Firmenich SA, Geneva, Switzerland). For spectral characterization see refs 2 and 23.

⁽²⁸⁾ Herlem, D.; Kervagoret, J.; Yu, D.; Khuong-Huu, F.; Kende, A. S. *Tetrahedron* **1993**, *49*, 607–618.





Reaction conditions:

(i) Bu₃SnH, cat. AIBN, 80°C, 12h. (ii) 1M (CH₂=CH)MgBr, THF, 10°C, 20 min. (iii) DMFDMA, xylene, reflux, 13h. (iv) LiBEt₃H, THF, -78°C, 5h. (v) CISO₃H, PrNO₂, -78°C, 9 min.

(Table 1). The action of ClSO₃H on **5** and **15a** is parallel to that observed with the other superacid FSO₃H on the same alcohols,^{12c} which means that both reagents induce biomimetic acid-mediated cyclizations with an internal nucleophilic termination by a hydroxyl group through the same reaction mechanism.^{12c} In contrast to the behavior of alcohol 15a, the reaction of (Z)-monocyclohomofarnesol (15b) with ClSO₃H (Table 1; entry 3) yielded a crude product basically composed of (\pm) -2 (only traces of 1 were detected) which means that cyclization of 15a to 1 competes with its isomerization to 15b, whose cyclization to **2** is more rapid in the superacid medium. In order to compare results, different cyclization agents, such as *p*-TsOH, SnCl₄ or H_2SO_4 , were also tested with 15a. Whereas the use of *p*-TsOH (entry 4) yields principally the monocyclized compound 10, and SnCl₄ (entry 5) does not yield a synthetically useful result, it is worth noting that the use of simple commercial sulfuric acid (entry 6) yielded a crude product with a very similar composition to that obtained with the superacid (entry 2).

In conclusion, a new straightforward approach to the preparation of racemic ambrox starting from β -ionone and (*E*)-nerolidol has been developed. This is based on the utilization of the rarely employed [2,3] sigmatropic rearrangement for creating β , γ -unsaturated dimethylamides and hence the alcohols to be cyclized.

Experimental Section

Gas chromatography (GC) was performed on a fused-silica capillary column (25 m \times 0.2 mm) coated with methylsilicone using nitrogen as carrier (25 mL min⁻¹) where the temperature program was from 50 °C to 220 °C (rate 5 °C min⁻¹) and from

220 °C to 280 °C (rate 3 °C min⁻¹). The retention times (t_R) are expressed in minutes. Thin-layer chromatography (TLC) was performed on precoated 0.25 mm-thick Merck plates of silica gel 60 F₂₅₄. Gravity column chromatography was carried out on Merck silica gel 60 (70–230 mesh) and low-pressure column chromatography on Merck silica gel 60 (230–400 mesh). All chromatographic separations were performed using hexane/Et₂O or hexane/*t*-BuOMe mixtures of increasing polarity and monitored by TLC and/or GC. IR spectra were obtained in liquid film between NaCl plates. ¹H NMR spectra were recorded from CDCl₃ solutions at 300 or 400 MHz and ¹³C NMR spectra at 75 or 100 MHz. Chemical shifts are reported in parts per million (δ) relative to TMS (δ 0.00) and coupling constants (*J*) are in hertz. Carbon substitution degrees were established by DEPT multipulse sequence. Mass spectra (MS) were recorded using an ionizing voltage of 70 eV.

Materials. β -Ionone (99% purity) was provided by Destilaciones García de la Fuente (Granada), and (+)-(*E*)-nerolidol (65% purity) was isolated from the essential oil of *Inula viscosa* L. THF was freshly distilled from Na (benzophenone) under argon. Other reagents and solvents were purchased from Aldrich Chemical Co. or Merck and were used as received.

Reaction of 3 with *N*,*N*-Dimethylformamide Dimethyl Acetal. A mixture of (+)-(*E*)-nerolidol (**3**) (1.30 g, 65% purity, 3.80 mmol), DMFDMA (3.80 g, 31.93 mmol), and xylene (10 mL) was refluxed for 13 h under continuous removal of methanol (Dean–Stark device). The mixture was directly concentrated *in vacuo* yielding a residue (1.47 g) which, after silica gel column chromatography, yielded Δ^{3E} -amide **4a** (575 mg, 54.6%, hexane: Et₂O 1:1, 4:6) and Δ^{3Z} -amide **4b** (258 mg, 24.4%, hexane:Et₂O 1:1).

(*E,E*)-4,8,12-Trimethyl-3,7,11-tridecatrienoic acid *N,N*dimethylamide (4a): $t_{\rm R}$ 39.75; IR 1648 (CONMe₂) cm⁻¹; ¹H NMR (400 MHz) δ 1.57 (br s, 6H), 1.63 (s, 3H), 1.65 (s, 3H), 2.91, 2.97 (2 s, 6H), 3.05 (d, 6.7, 2H), 5.04–5.10 (m, 2H), 5.30 (td, 6.7, 1.1, 1H); ¹³C NMR (100 MHz) δ 15.95, 16.41, 17.63, 25.64, 35.46, 37.31 (CH₃), 26.41, 26.67, 33.73, 39.55, 39.65 (CH₂), 116.82, 123.87, 124.27 (CH), 131.20, 135.11, 138.07, 172.05 (C); MS m/z (rel int) 277 (M⁺, 1), 208 (M⁺ - C₅H₉, 8), 194 (M⁺ - C₆H₁₁, 1), 154 (M⁺ - C₉H₁₅, 2), 141 (5), 140 (C₈H₁₄NO⁺, 7), 121 (12), 87 (21), 72 (CONMe₂⁺, 100), 69 (26), 41 (36).

(*E*,*Z*)-4,8,12-Trimethyl-3,7,11-tridecatrienoic acid *N*,*N*-dimethylamide (4b): $t_{\rm R}$ 38.95; IR 1648 (CONMe₂) cm⁻¹; ¹H NMR (400 MHz) δ 1.55 (br s, 6H), 1.63 (s, 3H), 1.70 (s, 3H), 2.88, 2.95 (2 s, 6H), 3.03 (d, 6.7, 2H), 5.01-5.10 (m, 2H), 5.29 (td, 6.7, 1.3, 1H); ¹³C NMR (100 MHz) δ 15.85, 17.56, 23.30, 25.56, 35.36, 37.23 (CH₃), 26.06, 26.56, 32.13, 33.14, 39.60 (CH₂), 117.51, 123.68, 124.16 (CH), 131.20, 135.34, 138.03, 171.87 (C); MS *m*/*z* (rel int) 277 (M⁺, 1), 208 (12), 195 (1), 154 (2), 141 (5), 140 (35), 121 (15), 87 (19), 72 (CONMe₂⁺, 100), 69 (29), 41 (47).

(E,E)-4,8,12-Trimethyl-3,7,11-tridecatrien-1-ol (5). To a solution of amide 4a (280 mg, 1.01 mmol) in anhyd THF (2 mL) was added dropwise (15 min) a 1 M solution of LiBEt₃H (superhydride) in THF (3.6 mL) at -78 °C under argon. After stirring for 7 h at -78 °C the reaction was allowed to warm, water (5 mL) was added, and the mixture was extracted with t-BuOMe (3 \times 20 mL). The combined organic layers were dried over anhyd Na₂SO₄ and concentrated to dryness, yielding a residue which, after silica gel purification, afforded 5 (178 mg, 74.7%, hexane: t-BuOMe 85:15) (lit.12c): t_R 30.98; IR 3343, 1047 (OH), 3050, 1670 (CH=C) cm⁻¹; ¹H NMR (300 MHz) δ 1.60 (s, 6H), 1.65 (s, 3H), 1.68 (s, 3H), 2.29 (br q, 7.3, 2H), 3.61 (t, 7.3, 2H), 5.06–5.17 (m, 3H); $^{13}\mathrm{C}$ NMR (75 MHz) δ 15.99, 16.18, 17.64, 25.65 (CH₃), 26.47, 26.72, 31.49, 39.68, 39.77, 62.41 (CH₂), 119.86, 123.97, 124.33 (CH), 131.27, 135.25, 138.84 (C); MS $m\!/z$ (rel int) 236 (M⁺, 0.4), 167 (M⁺ - C₅H₉, 1), 136 (6), 123 (C₉H₁₅⁺, 9), 95 $(C_7H_{11}^+, 9)$, 93 (9), 81 $(C_6H_9^+, 33)$, 69 $(C_5H_9^+, 100)$, 67 $(C_5H_7^+, 15), 41 (60).$

4-(2',6',6'-Trimethylcyclohex-1'-enyl)butan-2-one (12). Ketone **12** was prepared from β -ionone (**11**) by either catalytic hydrogenation (Raney-Ni/MeOH)²⁹ or reduction under phase transfer catalysis (Na₂S₂O₄, Adogen 464)³⁰ or free-radical reduction (Bu₃SnH, cat. AIBN),^{28,31} the last method being the most effective (91% yield; purity of **12**: 98%). Spectral data of **12** (IR, ¹H NMR, ¹³C NMR, MS) are according to that reported in the literature.^{12c,28,32}

3-Methyl-5-(2',6',6'-trimethylcyclohex-1'-enyl)-1-penten-3-ol (13). To a 1 M solution of vinylmagnesium bromide in THF (6.3 mL) was added dropwise (20 min) a solution of 12 (925 mg, 98% purity, 4.61 mmol) in anhyd THF (2 mL) at 10 °C under argon. After stirring for 20 min at 10 °C and a further 30 min at rt, a saturated NH₄Cl solution (30 mL) was added at 0 °C and the resulting mixture extracted with *t*-BuOMe (3×20 mL). The extract was washed with 10% NaHCO₃ solution and brine, dried over anhyd Na₂SO₄, and concentrated to yield 13 (985 mg, 96.3%) (lit.¹⁶): t_R 25.02; IR 3416, 1109 (tert OH), 3085, 1640, 997, 920 (CH=CH₂) cm⁻¹; ¹H NMR (300 MHz) δ 0.96 (s, 6H), 1.28 (s, 3H), 1.56 (s, 3H), 1.87 (br t, 6.2, 2H), 5.06 (dd, 10.7, 1.3, 1H), 5.21 (dd, 17.4, 1.3, 1H), 5.93 (dd, 17.4, 10.7, 1H); ¹³C NMR (75 MHz) δ 19.74, 27.49, 28.61 (CH_3), 19.48, 22.69, 32.73, 39.83, 42.30, 111.72 (CH₂), 144.91 (CH), 35.06, 73.53, 127.01, 136.59 (C); MS m/z (rel int) 222 (M⁺, 2), 204 (M⁺ - H₂O, 8), 189 (M⁺ $-CH_3 - H_2O$, 18), 147 (10), 137 (M⁺ - C₅H₉O, 8), 133 (25), 123 $(C_9H_{15}^+, 40), 121 (41), 107 (31), 95 (C_7H_{11}^+, 100), 93 (53), 81 (61),$ 79 (46), 71 (44), 55 (60), 43 (92), 41 (94)

Reaction of 13 with *N*,*N*-Dimethylformamide Dimethyl Acetal. Alcohol **13** (950 mg, 4.28 mmol) was treated with DMFDMA (3.06 g, 25.71 mmol) in xylene (10 mL) under the same conditions described for **3** to yield a residue (1.13 g) which, after silica gel column chromatography, afforded (*E*)-amide **14a** (594 mg, 50.1%, hexane:Et₂O 1:1, 4:6) and (*Z*)-amide **14b** (365 mg, 30.9%, hexane:Et₂O 1:1).

(*E*)-4-Methyl-6-(2',6',6'-trimethylcyclohex-1'-enyl)-3-hexenoic acid *N*,*N*-dimethylamide (14a): $t_{\rm R}$ 40.95; IR 1649

(CONMe₂) cm⁻¹; ¹H NMR (400 MHz) δ 0.95 (s, 6H), 1.56 (s, 3H), 1.67 (s, 3H), 1.87 (t, 6.3, 2H), 2.04 (s, 4H), 2.92, 2.99 (2 s, 6H), 3.06 (d, 6.7, 2H), 5.33 (t, 6.7, 1H); ¹³C NMR (100 MHz) δ 16.47, 19.76, 28.54, 35.46, 37.33 (CH₃), 19.46, 27.63, 32.68, 33.60, 39.75, 40.07 (CH₂), 116.26 (CH), 34.90, 127.04, 136.83, 138.91, 172.06 (C); MS *m*/*z* (rel int) 277 (M⁺, 2), 142 (26), 141 (19), 140 (C₈H₁₄-NO⁺, 7), 126 (C₇H₁₂NO⁺, 5), 95 (17), 87 (7), 72 (CONMe₂⁺, 100), 41 (20).

(Z)-4-Methyl-6-(2',6',6'-trimethylcyclohex-1'-enyl)-3-hexenoic acid N,N-dimethylamide (14b): $t_{\rm R}$ 39.86; IR 1649 (CONMe₂) cm⁻¹; ¹H NMR (400 MHz) δ 0.98 (s, 6H), 1.61 (s, 3H), 1.76 (d, 1.2, 3H), 1.88 (t, 6.3, 2H), 1.97-2.07 (m, 4H), 2.91, 2.97 (2 s, 6H), 3.07 (d, 6.8, 2H), 5.28 (td, 6.8, 1.2, 1H); ¹³C NMR (100 MHz) δ 19.77, 23.28, 28.54, 35.46, 37.26 (CH₃), 19.43, 26.85, 32.69, 32.87, 33.22, 39.71 (CH₂), 116.96 (CH), 34.90, 127.20, 136.80, 138.87, 171.93 (C); MS m/z (rel int) 277 (M⁺, 2), 142 (16), 141 (18), 140 (29), 126 (5), 95 (16), 87 (16), 72 (100), 41 (22).

(*E*)-4-Methyl-6-(2',6',6'-trimethylcyclohex-1'-enyl)-3-hexen-1-ol (15a). (*E*)-Amide 14a (476 mg, 1.72 mmol) was treated with superhydride (3.5 mL) for 4.5 h under the same conditions described for 4a, to yield a residue (398 mg) which, after silica gel purification, afforded 15a (348 mg, 85.7%, hexane:*t*-BuOMe 75:25) (lit.^{12c}): t_R 31.21; IR 3337, 1047 (OH) cm⁻¹; ¹H NMR (400 MHz) δ 0.98 (s, 6H), 1.59 (s, 3H), 1.68 (s, 3H), 1.89 (*t*, 6.3, 2H), 2.05 (s, 4H), 2.29 (br q, 7.3, 6.6, 2H), 3.63 (*q*, 6.2, 2H), 5.15 (br t, 7.3, 1H); ¹³C NMR (100 MHz) δ 16.29, 19.82, 28.60 (CH₃), 19.52, 27.87, 31.48, 32.74, 39.81, 40.34, 62.51 (CH₂), 119.07 (CH), 34.97, 127.07, 136.94, 139.90 (C); MS m/z (rel int) 236 (M⁺, 2), 191 (M⁺ - C₂H₅O, 2), 137 (M⁺ - C₆H₁₁O, 65), 95 (C₇H₁₁⁺, 100), 81 (C₆H₉⁺, 72), 67 (C₅H₇⁺, 28), 55 (27), 41 (64).

(*Z*)-4-Methyl-6-(*Z*',6',6'-trimethylcyclohex-1'-enyl)-3-hexen-1-ol (15b). (*Z*)-amide 14b (200 mg, 0.72 mmol) was treated with superhydride (1.5 mL) for 5 h, under the same conditions described for preparing alcohol 15a, to yield 15b (135 mg, 80%, hexane:*t*-BuOMe 8:2) (lit.¹²): $t_{\rm R}$ 30.80; IR 3325, 1048 (OH) cm⁻¹; ¹H NMR (400 MHz) δ 1.00 (s, 6H), 1.63 (s, 3H), 1.77 (s, 3H), 1.90 (*t*, 6.3, 2H), 1.98–2.12 (m, 4H), 2.29 (br q, 7.3, 6.5, 2H), 3.61 (*t*, 6.5, 2H), 5.09 (br t, 7.3, 1H); ¹³C NMR (100 MHz) δ 19.86, 23.44, 28.61 (CH₃), 19.49, 27.23, 31.46, 32.67, 32.74, 39.77, 62.62 (CH₂), 120.10 (CH), 34.92, 127.23, 136.91, 139.67 (C); MS *m*/*z* (rel int) 236 (M⁺, 2), 221 (M⁺ – CH₃, 1), 203 (M⁺ – CH₃ – H₂O, 1), 191 (2), 137 (75), 95 (100), 81 (76), 67 (29), 55 (33), 41 (69).

Cyclization of 5, 15a, 15b with ClSO₃H or H₂SO₄. General Procedure. To a solution of 99% ClSO₃H (0.2 mL, 1.99 mmol) or 98% H₂SO₄ (0.3 mL, 5.49 mmol) in 1-nitropropane (1-2 mL) was added dropwise (1-7 min) a solution of the alcohol (80 mg, 0.34 mmol) in 1-nitropropane (2 mL) at -78 °C under argon. After stirring for 6-25 min a saturated NaHCO₃ solution (1-2mL) was injected, and then further portions of solid NaHCO₃ were added. The mixture was extracted with *t*-BuOMe (3 \times 5 mL), and the combined organic layers were dried over anhyd Na₂SO₄ and concentrated to dryness to yield a crude product which was studied directly by GC-MS and ¹H NMR. Identification of compounds 1, 2, and 6-10 was effected by comparison of their MS data with those of authentic samples.²⁷ The product mixture distribution is presented in Table 1. Retention times (min) are: 1 (30.93), 2 (29.79), 6 (29.89), 7 (30.02), 8 (30.78), 9 (29.54), 10 (27.80).

Acknowledgment. We wish to thank Destilaciones García de la Fuente (Granada, Spain) for supporting this research.

Supporting Information Available: Spectral assignments and copies of ¹H NMR and ¹³C NMR spectra of compounds **4a**, **4b**, **5**, **12–15** (18 pages). This material is contained in libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information.

JO951908O

⁽²⁹⁾ Ohloff, G.; Schade, G. Angew. Chem. 1962, 74, 944.

⁽³⁰⁾ Camps, F.; Coll, J.; Guitart, J. Tetrahedron 1986, 42, 4603-4609.

⁽³¹⁾ Wolf, H. R.; Zink, M. P. *Helv. Chim. Acta* **1973**, *56*, 1062–1066. (32) Contento, M.; Savoia, D.; Claudio, T.; Umani-Ronchi, A. Synthesis **1979**, *1*, 30–32.